Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging.

Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Bull Exp Biol Med. 2006.

Organ: pineal-circadian · Type: clinical · Peptides: Epithalamin

A 12-year randomized clinical study of epithalamine in elderly patients with coronary disease and accelerated cardiovascular aging; the authors report lower all-cause and cardiovascular mortality versus the same basic therapy alone.

Editorial summary of a 2006 original article in Bulletin of Experimental Biology and Medicine. PubMed indexes the paper as a randomized controlled trial. Public pages cite PubMed only. Read the paper: PMID 17426848.

Methods

Twelve-year randomized clinical study of epithalamine (a pineal-gland peptide preparation; also spelled Epithalamin / Epithalamine) in elderly patients with coronary disease and accelerated aging of the cardiovascular system. Both arms received the same basic therapy; the treated arm also received long-term epithalamine. The English abstract does not give sample size, dose, or allocation details; those belong in the primary text. This page does not reprint the publisher PDF.

Findings

The authors report that long-term epithalamine decreased functional age and the degree of cardiovascular aging and increased exercise tolerance. After 12 years, deaths in the epithalamine group were 28% lower than in the control group despite the same basic therapy. They report cardiovascular mortality about two-fold lower, and the incidence of cardiovascular failure and respiratory disease about two-fold lower, in the treated group. They interpret this as a geroprotective effect on long-term prognosis in elderly subjects with accelerated aging.

This is one long-term trial from the originating groups. Independent replication is a separate question. It is not a product claim and not a current treatment guideline. Follow the PMID.